Summary: ResMed Inc's Global General Counsel, Michael J. Rider, completed a small personal sale of company stock on February 4, 2026, disposing of 50 shares at $260.00 apiece for a total of $13,000. The transaction was carried out under a Rule 10b5-1 plan that was adopted on February 28, 2025. Separately, ResMed reported fiscal second-quarter 2026 results that topped earnings expectations and met revenue forecasts, prompting some analysts to raise their price targets.
Transaction details
The sale reduced Rider's position by 50 shares while leaving him with direct ownership of 9,691 shares of ResMed common stock. The stock was trading at $271.56 at the time of reporting, and InvestingPro analysis noted the shares are slightly undervalued when compared to its Fair Value estimate.
Financial results that framed analyst reaction
ResMed reported adjusted earnings per share of $2.81 for the second quarter of fiscal 2026, above the analyst consensus of $2.73. Revenue for the quarter came in at $1.4 billion, matching expectations. Those results were central to analyst commentary and subsequent price-target revisions.
Analyst moves
- RBC Capital raised its price target for ResMed to $314, citing double-digit revenue and earnings growth that exceeded both its own and consensus estimates.
- KeyBanc Capital Markets increased its target to $302, describing the financial results as largely positive and supportive of its investment thesis.
- Needham maintained a Hold rating and highlighted that organic revenue growth improved to 8% in the second quarter from 7% in the first quarter, breaking a run of three consecutive quarters of slowing organic growth.
Market reaction
Despite the stronger-than-expected earnings and revenue in line with forecasts, ResMed's shares experienced a modest decline of 0.51% in aftermarket trading following the release. Analysts cited above remained largely optimistic in their outlooks.
Context and constraints
The details above are limited to the publicly disclosed insider transaction, the company-reported quarterly financials, and subsequent analyst actions. No additional explanations or motives for the insider sale are provided in the available information.